Aisling Capital Management LP Grows Stock Position in COMPASS Pathways PLC Sponsored ADR $CMPS

Key Points

• Aisling Capital Management LP increased its stake in COMPASS Pathways PLC by 24.3%, holding 1,198,418 shares, which represents about 1.2% of its holdings.
• Several hedge funds, including Vivo Capital LLC and Nantahala Capital Management LLC, have significantly increased their positions in COMPASS Pathways, indicating growing institutional interest.
• COMPASS Pathways reported a loss per share of ($0.38), missing estimates, while analysts maintain a Moderate Buy rating with a target price averaging $16.29.

Aisling Capital Management LP increased its holdings in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 24.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 1,198,418 shares of the company's stock after purchasing an additional 233,918 shares during the period. COMPASS Pathways makes up approximately 1.2% of Aisling Capital Management LP's holdings, making the stock its 7th largest position. Aisling Capital Management LP owned 1.29% of COMPASS Pathways worth $3,427,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Cerity Partners LLC acquired a new position in shares of COMPASS Pathways during the 1st quarter worth about $29,000. GAMMA Investing LLC lifted its position in shares of COMPASS Pathways by 93.6% during the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock worth $30,000 after purchasing an additional 5,003 shares during the last quarter. Flagship Harbor Advisors LLC lifted its position in shares of COMPASS Pathways by 27.7% during the 1st quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock worth $41,000 after purchasing an additional 3,134 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in shares of COMPASS Pathways during the 1st quarter worth about $41,000. Finally, OLD National Bancorp IN acquired a new position in shares of COMPASS Pathways during the 1st quarter worth about $45,000. Institutional investors and hedge funds own 46.19% of the company's stock.

Wall Street Analysts Forecast Growth

CMPS has been the subject of several research analyst reports. Evercore ISI reissued an "in-line" rating and set a $6.00 price objective (down previously from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $12.00 price target on shares of COMPASS Pathways in a report on Tuesday, May 27th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 price target on shares of COMPASS Pathways in a report on Friday, August 1st. Finally, HC Wainwright cut their price target on COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a report on Monday, August 4th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $16.29.

COMPASS Pathways Price Performance

Shares of CMPS traded down $0.2050 during mid-day trading on Tuesday, reaching $4.0550. The company had a trading volume of 822,222 shares, compared to its average volume of 1,805,311. COMPASS Pathways PLC Sponsored ADR has a twelve month low of $2.25 and a twelve month high of $8.54. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.82 and a quick ratio of 8.82. The company's 50-day moving average is $3.98 and its 200-day moving average is $3.84. The company has a market capitalization of $389.04 million, a P/E ratio of -2.21 and a beta of 2.17.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). On average, equities analysts anticipate that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.